Skip to main content
Premium Trial:

Request an Annual Quote

Ambry, Agilent Ink Target Enrichment Alliance

NEW YORK (GenomeWeb News) – Ambry Genetics will use Agilent Technologies' SureSelect Target Enrichment System for the exome sequencing services it provides for its customers, the firms announced today.

"With Agilent’s SureSelect, Ambry Genetics is offering whole exome capture services for cancer markers, drug response, and Mendelian disease gene discovery," Ardy Arianpour, VP of business development for Ambry, said in a statement. "Ambry’s exome sequencing services deliver state of the art bioinformatics which include variant filtering, annotation, and interpretation of candidate mutations."

Financial and other terms of the alliance were not disclosed.

Agilent launched the SureSelect platform in 2009 and now includes a portfolio of 21 catalog and custom target enrichment products, the firms said.

A couple of months ago, Agilent announced that Expression Analysis was named a certified service provider for the SureSelect Target Enrichment System for next-generation sequencing. That followed BGI becoming a CSP for the platform earlier in the year.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.